Molecular Diversity

, Volume 21, Issue 3, pp 533–546 | Cite as

Synthesis, pharmacological evaluation and molecular docking of pyranopyrazole-linked 1,4-dihydropyridines as potent positive inotropes

  • Rakesh KumarEmail author
  • Neha Yadav
  • Rodolfo Lavilla
  • Daniel Blasi
  • Jordi Quintana
  • José Manuel Brea
  • María Isabel Loza
  • Jordi Mestres
  • Mamta Bhandari
  • Ritu Arora
  • Rita Kakkar
  • Ashok K. Prasad
Original Article


1,4-Dihydropyridines are well-known calcium channel blockers, but variations in the substituents attached to the ring have resulted in their role reversal making them calcium channel activators in some cases. We describe the microwave-assisted eco-friendly approach for the synthesis of pyranopyrazole-1,4-dihydropyridines, a new class of 1,4-DHPs, under solvent-free conditions in good yield, and screen them for various in silico, in vitro and in vivo activities. The in vivo experimentation results show that the compounds possess positive inotropic effect, and the docking results validate their good binding with calcium channels. Compounds 7c, 7g and 7i appear to be the most effective positive inotropes, even at low doses, and bind with the calcium channels even more strongly than Bay K 8644, a well-known calcium channel activator. The chronotropic effect for the new compounds was also studied. The target and off-target affinity profiling supported the in vivo results and revealed that the hybridized pyranopyrazole dihydropyridine scaffold has delivered new moderate hits, to be optimized, for the cytochrome P450 3A4 enzymes, opening avenues for combined pharmacological activity through standard structural modification.

Graphical Abstract


Pyranopyrazole-1 4-Dihydropyridines Inotropic effect Molecular docking Structure–activity analysis CYP450 inhibition Microwave synthesis \(\hbox {SeO}_{2}\) 



This work was partially supported by ChemBiobank, the Chemical Biology infrastructure initiative in Spain, carrying out the predictive and the biological activity of the synthesized compounds. The authors would like to thank CDRI, Lucknow, for carrying out the in vivo studies, Defence Research and Development Organization (DRDO) for financial support and University of Delhi, Delhi, for providing the laboratory and instrumentation facility.

Supplementary material

11030_2017_9738_MOESM1_ESM.docx (6 mb)
Supplementary Data Supplementary data (1H NMR, 13C NMR spectra and UPLC-MS results) associated with this article can be found. (doc 5.98MB)


  1. 1.
    Carafoli E, Klee C (1999) Calcium as cellular regulator. Oxford University Press, New York, pp 171–200Google Scholar
  2. 2.
    William JE, Venkata CSR (2011) Calcium channel blockers. J Clin Hypertens 13:687–689. doi: 10.1111/j.1751-7176.2011.00513 CrossRefGoogle Scholar
  3. 3.
    Bossert F, Meyer H, Wehinger E (1981) 4-Aryldihydropyridines, a new class of highly active calcium antagonists. Angew Chem Int Edit 20:762–769. doi: 10.1002/anie.198107621 CrossRefGoogle Scholar
  4. 4.
    Sohal HS, Goyal A, Sharma R, Khare R (2014) One-pot multicomponent synthesis of symmetrical Hantzsch 1,4-dihydropyridine derivatives using glycerol as clean and green solvent. Eur J Med Chem 5:171–175. doi: 10.5155/eurjchem.5.1.171-175.943 CrossRefGoogle Scholar
  5. 5.
    Ali HI, Ashida N, Nagamatsu T (2007) Design, synthesis, antitumor activity, and molecular docking study of novel 2-methylthio-, 2-amino-, and 2-(\(N\)-substituted amino)-10-alkyl-2-deoxo-5-deazaflavins. Bioorg Med Chem 15:6336–6352. doi: 10.1016/j.bmc.2007.06.058 CrossRefPubMedGoogle Scholar
  6. 6.
    Pavani MG, Nunez M, Brigidi P, Vitali B, Gambari R (2002) Antimicrobial and antitumor activity of \(N\)-heteroimmine-1,2,3-dithiazoles and their transformation in triazolo-, imidazo-, and pyrazolopirimidines. Bioorg Med Chem 10:449–456. doi: 10.1016/S0968-0896(01)00294-2 CrossRefPubMedGoogle Scholar
  7. 7.
    Sondhi SM, Johar M, Rajvanshi S, Dastidar SG, Shukla R, Raghubir R, Lown JW (2001) Anticancer, anti-inflammatory and analgesic activity evaluation of heterocyclic compounds synthesized by the reaction of 4-isothiocyanato-4-methylpentan-2-one with substituted \(o\)-phenylenediamines, \(o\)-diaminopyridine and (Un)substituted. Aust J Chem 54:69–74. doi: 10.1071/CH00141 CrossRefGoogle Scholar
  8. 8.
    Narayana LB, Rao RRA, Rao SP (2009) Synthesis of new 2-substituted pyrido[2,3-\(d\)]pyrimidin-4(1H)-ones and their antibacterial activity. Eur J Med Chem 44:1369–1376. doi: 10.1016/j.ejmech.2008.05.025 CrossRefGoogle Scholar
  9. 9.
    Trivedi A, Dodiya D, Dholariya B, Kataria V, Bhuva V, Shah V (2011) Synthesis and biological evaluation of some novel 1,4-dihydropyridines as potential antitubercular agents. Chem Biol Drug Des 78:881–886. doi: 10.1111/j.1747-0285.2011.01233.x CrossRefPubMedGoogle Scholar
  10. 10.
    Shishoo CJ, Shirsath VS, Rathod IS, Patil MJ, Bhargava SS (2001) Design, synthesis and antihistaminic (H1) activity of some condensed 2-(substituted) arylaminoethylpyrimidine-4-(3\(H\))-ones. Arzneim Forsch 51:221–231Google Scholar
  11. 11.
    Jiang J, Rhee MA, Melman N, Ji X, Jacobson KA (2006) 6-Phenyl-1,4-dihydropyridine derivatives as potent and selective A3 adenosine receptor antagonists. J Med Chem 39:4667–4675. doi: 10.1021/jm960457c CrossRefGoogle Scholar
  12. 12.
    Li AH, Chang L, Ji X, Melman N, Jacobson KA (2009) Functionalized congeners of 1,4-dihydropyridines as antagonist molecular probes for A3 adenosine receptors. Bioconjug Chem 10:667–677. doi: 10.1021/bc9900136 CrossRefGoogle Scholar
  13. 13.
    Bakali JE, Gilleron P, Malapel MB, Mansouri R, Muccioli GG, Djouina M, Barczyk A, Klupsch F, Andrzejak V, Lipka E, Furman C, Lambert DM, Chavatte P, Desreumaux P, Millet R (2012) 4-Oxo-1,4-dihydropyridines as selective CB2 cannabinoid receptor ligands. Part 2: Discovery of new agonists endowed with protective effect against experimental colitis. J Med Chem 55:8948–8952. doi: 10.1021/jm3008568 CrossRefPubMedGoogle Scholar
  14. 14.
    Nantermet PG, Barrow JC, Selnick HG, Homnick CF, Freidinger RM, Chang RS, O’Malley SS, Reiss DR, Broten TP, Ransom RW, Pettibone DJ, Olah T, Forray C (2000) Selective \(\upalpha \)1a adrenergic receptor antagonists based on 4-aryl-3,4-dihydropyridine-2-ones. Bioorg Med Chem Lett 10:1625–1628. doi: 10.1016/S0960-894X(99)00696-4 CrossRefPubMedGoogle Scholar
  15. 15.
    Niwa T, Shiraga T, Hashimoto T, Kagayama A (2004) Effect of Nilvadipine, a dihydropyridine calcium antagonist, on cytochrome P450 activities in human hepatic microsomes. Biol Pharm Bull 27:415–417. doi: 10.1248/bpb.27.415 CrossRefPubMedGoogle Scholar
  16. 16.
    Viegas-Junior C, Danuello A, Silva DBV, Barreiro EJ, Fraga CA (2007) Molecular hybridization: a useful tool in the design of new drug prototypes. Curr Med Chem 14:1829–1829. doi: 10.2174/092986707781058805 CrossRefPubMedGoogle Scholar
  17. 17.
    Huang LJ, Hour MJ, Teng CM, Kuo SC (1992) Synthesis and antiplatelet activities of \(N\)-arylmethyl-3,4-dimethylpyrano[2,3-\(c\)]pyrazol-6-one derivatives. Chem Pharm Bull 40:2547–2551CrossRefPubMedGoogle Scholar
  18. 18.
    Mohamed NR, Khaireldin NY, Fahmyb AF, El-Sayeda AAF (2010) Facile synthesis of fused nitrogen containing heterocycles as anticancer agents. Der Pharm Chem 2:400–417Google Scholar
  19. 19.
    Ueda T, Mase H, Oda N, Ito I (1981) Synthesis of pyrazolone derivatives. XXXIX. Synthesis and analgesic activity of pyrano[2,3-\(c\)]pyrazoles. Chem Pharm Bull 29:3522–3528. doi: 10.1248/cpb.29.3522 CrossRefPubMedGoogle Scholar
  20. 20.
    Kuo SC, Huang LJ, Nakamura H (1984) Synthesis and analgesic and antiinflammatory activities of 3,4-dimethylpyrano[2,3-\(c\)]pyrazol-6-one derivatives. J Med Chem 27:539–544. doi: 10.1021/jm00370a020 CrossRefPubMedGoogle Scholar
  21. 21.
    Assiery SE, Sayed GH, Fouda A (2004) Synthesis of some new annulated pyrazolo-pyrido (or pyrano) pyrimidine, pyrazolopyridine and pyranopyrazole derivatives. Acta Pharma 54:143–150Google Scholar
  22. 22.
    Mohammad MM, Mohammad RJ, Mohammad B (2006) Facile synthesis of pyrano[2,3-\(c\)]pyrazol-6-one derivatives under microwave irradiation in solvent-free conditions. Synth Comm 36:51–58. doi: 10.1080/00397910500328886 CrossRefGoogle Scholar
  23. 23.
    Noda M, Shimizu S, Tanabe T, Takai T, Kayano T, Ikeda T, Takahashi H, Nakayama H, Kanaoka Y, Minamino N (1984) Primary structure of electrophorus electricus sodium channel deduced from cDNA sequence. Nature 312:121–127. doi: 10.1038/312121a0 CrossRefGoogle Scholar
  24. 24.
    Tanabe T, Takeshima H, Mikami A, Flockerzi V, Takahashi H, Kanqawa A, Kojima M, Matsuo H, Hirose T, Numa S (1987) Primary structure of the receptor for calcium channel blockers from skeletal muscle. Nature 328:313–318. doi: 10.1038/328313a0 CrossRefGoogle Scholar
  25. 25.
    Tempel BL, Papazian DM, Schwarz TL, Jan LY, Jan YN (1987) Sequence of a probable potassium channel component encoded at Shaker locus of Drosophila. Science 237:770–775. doi: 10.1126/science.2441471 CrossRefPubMedGoogle Scholar
  26. 26.
    Friesner RA, Banks JL, Murphy RB, Halgren TA, Klicic JJ, Mainz DT, Repasky MP, Knoll EH, Shelley M, Perry JK, Shaw DE, Francis P, Shenkin PS (2004) Glide: a new approach for rapid, accurate docking and scoring. 1. Method and assessment of docking accuracy. J Med Chem 47:1739–1749. doi: 10.1021/jm0306430 CrossRefPubMedGoogle Scholar
  27. 27.
    Halgren TA, Murphy RB, Friesner RA, Beard HS, Frye LL, Pollard WT, Banks JL (2004) Glide: a new approach for rapid, accurate docking and scoring. 2. Enrichment factors in database screening. J Med Chem 47(7):1750–1759. doi: 10.1021/jm030644s CrossRefPubMedGoogle Scholar
  28. 28.
    Halgren TA (2009) Identifying and characterizing binding sites and assessing druggability. J Chem Inf Model 49(2):377–389. doi: 10.1021/ci800324m CrossRefPubMedGoogle Scholar
  29. 29.
    Tikhonov DB, Zhorov BS (2005) Modeling P-loops domain of sodium channel: homology with potassium channels and interaction with ligands. Biophys J 88:184–197. doi: 10.1529/biophysj.104.048173 CrossRefPubMedGoogle Scholar
  30. 30.
    Tikhonov DB, Zhorov BS (2008) Molecular modeling of benzothiazepine binding in the L-type calcium channel. J Biol Chem 283:17594–17604. doi: 10.1074/jbc.M800141200 CrossRefPubMedGoogle Scholar
  31. 31.
    Yamaguchi S, Zhorov BS, Yoshioka K, Nagao T, Ichijo H, Adachi-Akahane S (2003) Key roles of Phe1112 and Ser1115 in the pore-forming IIIS5–S6 linker of L-type Ca\(^{2+}\) channel alpha1C subunit (CaV 1.2) in binding of dihydropyridines and action of Ca\(^{2+}\) channel agonists. Mol Pharmacol 64:235–248. doi: 10.1124/mol.64.2.235 CrossRefPubMedGoogle Scholar
  32. 32.
    Vidal D, Garcia-Serna R, Mestres J (2011) Ligand-based approaches to in silico pharmacology. Methods Mol Biol 672:489–502. doi: 10.1007/978-1-60761-839-3_19 CrossRefPubMedGoogle Scholar
  33. 33.
    Garcia-Serna R, Vidal D, Remez N, Mestres J (2015) Large-scale predictive drug safety: from structural alerts to biological mechanisms. Chem Res Toxicol 28:1875–1887. doi: 10.1021/acs.chemrestox.5b00260 CrossRefPubMedGoogle Scholar
  34. 34.
    Gaulton A, Hersey A, Nowotka M, Bento AP, Chambers J, Mendez D, Mutowo P, Atkinson F, Bellis LJ, Cibrián-Uhalte E, Davies M, Dedman N, Karlsson A, Magariños MP, Overington JP, Papadatos G, Smit I, Leach AR (2017) The ChEMBL database in 2017. Nucleic Acids Res 45:D945–D954. doi: 10.1093/nar/gkw1074 CrossRefPubMedGoogle Scholar
  35. 35.
    Matsui T, Takeuchi M, Yamagishi S (2010) Nifedipine, a calcium channel blocker, inhibits inflammatory and fibrogenic gene expressions in advanced glycation end product (AGE)-exposed fibroblasts via mineralocorticoid receptor antagonistic activity. Biochem Biophys Res Commun 396:566–570. doi: 10.1016/j.bbrc.2010.04.149 CrossRefPubMedGoogle Scholar
  36. 36.
    Jorgensen WL, Maxwell DS, Tirado-Rives J (1996) Development and testing of the OPLS all-atom force field on conformational energetics and properties of organic liquids. J Am Chem Soc 118:11225–11236. doi: 10.1021/ja9621760 CrossRefGoogle Scholar
  37. 37.
    SiteMap (2009) version 2.3, Schrödinger. LLC, New York, NYGoogle Scholar
  38. 38.
    Keiser MJ, Roth BL, Armbruster BN, Ernsberger P, Irwin JJ, Shoichet BK (2007) Relating protein pharmacology by ligand chemistry. Nat Biotechnol 25:197–206. doi: 10.1038/nbt1284 CrossRefPubMedGoogle Scholar
  39. 39.
    Briansó F, Carrascosa MC, Oprea TI, Mestres J (2011) Cross-pharmacology analysis of G protein-coupled receptors. Curr Top Med Chem 11:1956–1963. doi: 10.2174/156802611796391285
  40. 40.
    Areias FM, Brea J, Gregori-Puigjané E, Zaki MEA, Carvalho MA, Domínguez E, Gutiérrez-de-Terán H, Proença MF, Loza MI, Mestres J (2010) In silico directed chemical probing of the adenosine receptor family. Bioorg Med Chem 18:3043–3052. doi: 10.1016/j.bmc.2010.03.048 CrossRefPubMedGoogle Scholar
  41. 41.
    Mestres J, Seifert SA, Oprea TI (2011) Linking pharmacology to clinical reports: cyclobenzaprine and its possible association with serotonin syndrome. Clin Pharmacol Ther 90:662–665. doi: 10.1038/clpt.2011.177 CrossRefPubMedGoogle Scholar
  42. 42.
    Antolín AA, Jalencas X, Yélamos J, Mestres J (2012) Identification of PIM kinases as novel targets for PJ34 with confounding effects in PARP biology. ACS Chem Biol 7:1962–1967. doi: 10.1021/cb300317y CrossRefPubMedGoogle Scholar
  43. 43.
    Antolín AA, Mestres J (2015) Distant polypharmacology among MLP chemical probes. ACS Chem Biol 10:395–400. doi: 10.1021/cb500393m CrossRefPubMedGoogle Scholar
  44. 44.
    Montolio M, Gregori-Puigjané E, Pineda D, Mestres J, Navarro P (2012) Identification of small molecule inhibitors of amyloid \(\upbeta \)-induced neuronal apoptosis acting through the imidazoline I(2) receptor. J Med Chem 55:9838–9846. doi: 10.1021/jm301055g CrossRefPubMedGoogle Scholar
  45. 45.
    Waller CL, Juma BW, Gray LE Jr, Kelce WR (1996) Three-dimensional quantitative structure-activity relationships for androgen receptor ligands. Toxicol Appl Pharmacol 137:219–227. doi: 10.1006/taap.1996.0075 CrossRefPubMedGoogle Scholar
  46. 46.
    Stefanachi A, Nicolotti O, Leonetti F, Cellamare S, Campagna F, Loza MI, Brea JM, Mazza F, Gavuzzo E, Carotti A (2008) 1,3-Dialkyl-8-(hetero)aryl-9-OH-9-deazaxanthines as potent A2B adenosine receptor antagonists: design, synthesis, structure-affinity and structure-selectivity relationships. Bioorg Med Chem 16:9780–9789. doi: 10.1016/j.bmc.2008.09.067 CrossRefPubMedGoogle Scholar

Copyright information

© Springer International Publishing Switzerland 2017

Authors and Affiliations

  • Rakesh Kumar
    • 1
    Email author
  • Neha Yadav
    • 1
  • Rodolfo Lavilla
    • 2
  • Daniel Blasi
    • 3
  • Jordi Quintana
    • 3
  • José Manuel Brea
    • 4
  • María Isabel Loza
    • 4
  • Jordi Mestres
    • 5
  • Mamta Bhandari
    • 1
  • Ritu Arora
    • 1
  • Rita Kakkar
    • 1
  • Ashok K. Prasad
    • 1
  1. 1.Bio-organic Laboratory, Department of ChemistryUniversity of DelhiDelhiIndia
  2. 2.Laboratory of Organic Chemistry, Department of Pharmacology and Therapeutical Chemistry, Faculty of PharmacyUniversity of BarcelonaBarcelonaSpain
  3. 3.Drug Discovery PlatformParc Científic de BarcelonaBarcelonaSpain
  4. 4.USEF Screening Platform, Centre of Research on Molecular Medicine and Chronic Diseases (CIMUS)Universidad de Santiago de Compostela (USC)Santiago de CompostelaSpain
  5. 5.Systems Pharmacology, Research Program on Biomedical Informatics (GRIB)IMIM Hospital del Mar Medical Research Institute and University Pompeu FabraBarcelonaSpain

Personalised recommendations